CD180

Across TCGA pan-cancer cohorts, CD180 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD180 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CD180 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD180 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KIRC, SKCM, and UCEC are the cancer types where CD180 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.154	0.631	.003	12	view →
SKCM	DFS	Median	III,IV	0.996	0.593	.020	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD180–KIRC (OS)

Open the KIRC breakdown →